Paul is a highly regarded physician and healthcare executive with deep experience in both the academic and patient care spaces. He offers clients critical insights across a wide range of clinical areas and healthcare technologies, and provides guidance on Medicare policy and regulatory requirements. Paul also has significant experience in health outcomes research and scientific computing.
Before joining McDermottPlus, Paul served as chief medical officer and MolDX director of clinical science at a commercial provider and Medicare Administrative Contracting company. MolDX has a contract with the Centers for Medicare & Medicaid Services to review and make coverage and payment determinations for new molecular medicine technologies. In this role, he was instrumental in forging consensus among Medicare contractors on emerging and sometimes controversial areas of medicine in a highly visible program, and served as a primary point of contact between MolDX and the Centers for Medicare & Medicaid Services. He also played a critical role in the development of strategic directions for molecular diagnostics, post-acute care, and data analytics.
Prior to that role, Paul worked in private practice in New England, where he advised acute care and post-acute care institutions as well as academic departments on Medicare coverage, billing, and quality measures. In addition to being centrally involved in administrative legal hearings regarding denied payment cases, he also worked closely with various stakeholders to develop a data-driven strategy that was used to enhance care quality and safety, including improving patient satisfaction and hospital readmissions.
Paul served on served on the National Quality Forum Scientific methods panel while in private practice and currently serves on the American Medical Association (AMA) Proprietary Laboratory Analyses (PLA) – Technical Advisory Group (TAG).
